Form 4: Bionano Genomics GC Reports Tax Withholding Transaction

General Counsel Jonathan V. Dixon reported the withholding of 24 shares of Bionano Genomics common stock to satisfy tax obligations.

Summary

• Jonathan V. Dixon, General Counsel of Bionano Genomics, Inc., executed a transaction involving the withholding of 24 shares of common stock.
• The transaction occurred on June 3, 2026, at a price of $1.30 per share.
• The withholding was conducted to satisfy tax obligations related to the vesting of Restricted Stock Units (RSUs) granted on June 3, 2024.
• Following this transaction, the reporting person holds 239 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a mandatory tax-related transaction rather than a strategic shift or market-driven trade.

Positives

• The transaction is a routine administrative action related to tax withholding upon the vesting of equity compensation, rather than a discretionary sale.

Negatives

• The transaction reflects a reduction in the reporting person's direct equity holdings.

Risks

• None identified; this is a standard tax-related transaction.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of insider equity activity common in the biotechnology sector, where RSU vesting schedules frequently trigger automatic tax withholding transactions.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices for equity compensation management in publicly traded U.S. companies.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a standard administrative tax settlement.

Next Steps

• None

Key Dates

Keywords

Bionano Genomics, BNGO, Insider Trading, Form 4, Tax Withholding, Equity Compensation